Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-cash Items: 2020-2023

Historic Non-cash Items for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2023 value amounting to $131.8 million.

  • Mirum Pharmaceuticals' Non-cash Items rose 155.17% to $131.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $131.8 million, marking a year-over-year increase of 155.17%. This contributed to the annual value of $131.8 million for FY2023, which is 155.17% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Non-cash Items of $131.8 million as of Q4 2023, which was down 13.65% from $152.6 million recorded in Q3 2023.
  • In the past 5 years, Mirum Pharmaceuticals' Non-cash Items registered a high of $152.6 million during Q3 2023, and its lowest value of $32.6 million during Q4 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Non-cash Items had a median value of $57.8 million in 2022 and averaged $74.7 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first declined by 19.67% in 2021, then skyrocketed by 155.17% in 2023.
  • Quarterly analysis of 4 years shows Mirum Pharmaceuticals' Non-cash Items stood at $40.6 million in 2020, then declined by 19.67% to $32.6 million in 2021, then soared by 58.24% to $51.6 million in 2022, then soared by 155.17% to $131.8 million in 2023.
  • Its Non-cash Items stands at $131.8 million for Q4 2023, versus $152.6 million for Q3 2023 and $102.2 million for Q2 2023.